A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)) (ROCKnrol-1)
-
Enrollment
This study is currently enrolling. -
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Sanofi-Aventis Research & Development
Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in event free survival.
Enrollment Form
This study is currently enrolling.